Background {#Sec1}
==========

Psychopharmacological treatment in the child and adolescents with psychiatric disorder is increasingly becoming a matter of concern both in the western worlds and developing countries \[[@CR1], [@CR2]\]. Of greater concern is the rate of off-label use of psychotropic medication and polypharmacy especially in the developing countries \[[@CR2]\] where the practice of specialized care is still very rudimentary. Some patients might present with more than one psychiatric diagnosis or resistance to monotherapy, necessitating the use of multiple psychotropic medications or other non-evidenced based methods of care \[[@CR3]--[@CR5]\]. Other instances are the use of another medication to treat the adverse reaction of an effective agent or adjunctive use of medications (adjunctive polypharmacy) and augmentation (augmentation polypharmacy) \[[@CR3], [@CR4], [@CR6], [@CR7]\]. In psychiatry, polypharmacy has been defined by the National Association of State Mental Health Program Directors (NASMHPD) as the use of two or more psychiatric medications in the same patient \[[@CR6], [@CR7]\]. NASMHPD described other types of polypharmacy: *"Same-class polypharmacy"*, where agents from the same class are used for the same symptoms, e.g., use of two types of Phenothiazines in a case of psychosis; *"Multi-class polypharmacy"*, use of more than one agents from different classes for the same disorder, e.g., carbamazepine and olanzapine for mania; and *"Total polypharmacy"* which is described as 'total drug load' including non-psychotropic medications e.g., ibuprofen for co-morbid aches \[[@CR4], [@CR6], [@CR7]\].

There is a high prevalence of psychiatric polypharmacy in child and adolescents ranging from 2.9--27% worldwide \[[@CR8], [@CR9]\]. Another study from India, with a smaller sample size among inpatients reported a rate of 52% \[[@CR10]\]. While there is little evidence to support this practice, there are growing concerns on the adverse effect of combining two or more medications \[[@CR3], [@CR4]\]. It compounds regimens complexity leading to non-compliance to treatment and increases the effects of drug interaction. Some medications affect liver enzymes, hence the bio-availability and therapeutic effect of drugs. For example, carbamazepine which is an enzyme inducer may reduce the effectiveness of some antipsychotics \[[@CR3], [@CR4]\]. Moreover, the fact that children often need longer duration of treatment exposes them to more adverse effects of polypharmacy or drug interaction \[[@CR2], [@CR3], [@CR9]\].

To the best of our knowledge, there is a dearth of data on polypharmacy in child and adolescent mental health in Africa, especially Botswana where children and adults are treated in the same facility by general adult psychiatrists. This study was designed to assess the prevalence and the risk factors of psychiatric polypharmacy among children and adolescents treated at our referral hospital between 1 January 2012 and 31 July December 2016. This we believe will add more weight to the on-going advocacy on the need for specialized care for children and adolescents in Botswana.

Methods {#Sec2}
=======

After obtaining institutional ethics approval, we reviewed the records of children and adolescents aged below 18 years between 1 January 2012 and 31 July 2016 who presented with psychiatric disorders. The study was conducted in Sbrana Psychiatric Hospital (SPH) Lobatse, located in the south western district of Botswana. It is the only tertiary mental institution in the country with facilities to cater for all general adult as well as paediatric psychiatric patients, and it accepts all types of mental disorders, ranging from minor to severe conditions. Data were retrieved from the patients' medical records comprising socio-demographics, diagnosis and treatments (including follow-up notes) using a form designed by the authors. The diagnosis was extracted from the most prominent and consistent group of symptoms using ICD-10 classification and as indicated by the members of the multidisciplinary care teams. Only subjects who had pharmacotherapy alone or both pharmacotherapy and psychotherapy were studied. Polypharmacy was only considered when two or more psychotropic medications (i.e., antipsychotics, antidepressants, anticholinergics, stimulants, mood stabilizers, etc.) were used at the same treatment period (i.e., same class, adjunctive, multi-class and augmentation polypharmacy), not total polypharmacy. We excluded cases where switching of psychiatric medications were established from documentation, either in the same episode or different episodes. We also excluded patients who received only psychotherapy such as counselling, psycho-education and cognitive behavioral therapy. Out of a total of 238 patients treated during the study period; 118 who had only psychotherapy were excluded. The disorders were grouped into externalizing conditions (conduct disorder and hyperkinetic disorder), internalizing (anxiety disorder and mood disorders) and others (epilepsy, enuresis, somatoform disorder, psychosis, conversion disorder, etc). We used age 10 years as cut-off between the younger child and older child for our analysis.

Data Analysis was done using the Statistical Package for Social Sciences (SPSS for windows 16.0, SPSS Inc., Chicago, IL, USA). Frequency tables were employed for descriptive statistics such as socio-demographics and clinical variables. Cross-tabulations were done to show the relationships between relevant socio-demographics (such as age group, birth order), clinical variable and polypharmacy. Chi-square test was used to determine associations between the categorical variables. Predictor variables (i.e., independent factors) for identified dependent variables which is polypharmacy was further investigated using binary logistic regression analysis. The level of statistical significance for all tests was set at *p* \< 0.05.

Results {#Sec3}
=======

Only 120 subjects met the inclusion criteria. The mean age (sd) of the subjects was 11.9 (4.4) years (67.5% males, 32.5% females). Forty-six (38.3%) were 10 years and below (Table [1](#Tab1){ref-type="table"}).Table 1Socio-demographic characteristics of children and adolescents with psychiatric disorders in Sbrana Psychiatric Hospital Lobatse, Botswana, January 2012 to July 2016VariableN (%)Age (years, M = 11.94, SD = 4.4)Age group120 (100) ≤ 1046 (38.3) \>10 years74 (61.7)Gender120 (100) Male81 (67.5) Female39 (32.5)Birth order^a^115 (100) First child41 (35.7) Others74 (64.3)^a^N not equal to 120 due to missing data

The disorder grouped as others comprising epilepsy, enuresis, somatoform disorder, psychosis, conversion disorder, etc. had the highest proportion 70 (58.3%), followed by externalizing disorders 43 (35.8%) and internalizing disorders 7 (5.8%). Sixty-nine (57%) patients had co-morbid psychiatric disorders while 35 (29.2%) had 2 or more psychotropic medications (polypharmacy) (Table [2](#Tab2){ref-type="table"}).Table 2Detailed clinical variables in children and adolescents with psychiatric disorders in Sbrana Psychiatric Hospital Lobatse, Botswana, January 2012 to July 2016VariablesN (%)Disorders120 (100) Externalizing disorders43 (35.8) Internalizing disorders7 (5.8) Other disorders70 (58.3)Past psychiatric history120 (100) Absent24 (20) Present96 (80)Past medical history120 (100) Absent109 (90.8) Present11 (9.2)Psychiatric co-morbidity120 (100) Absent51 (42.5) Present69 (57.5)Physical/medical comorbidity120 (100) Absent106 (83.3) Present14 (11.7)Mode of care120 (100) In-patient31 (25.8) Out-patient89 (74.2)Prescribing pattern120 (100) Monotherapy85 (70.8) Poly-therapy35 (29.2)

The factors with significant association with polypharmacy were age group (χ^2^ = 5.319, *p* = 0.021), psychiatrist care (*χ* ^*2*^ = 5.772, *p* = 0.016), psychiatric co-morbidity (χ^2^ = 7.802, *p* = 0.005) and psychotropic side effect (*χ* ^*2*^ = 6.640, *p* = 0.010) using Chi-square test (Table [3](#Tab3){ref-type="table"}). The logistic regression analyses indicated that the significant risk factors of polypharmacy were psychiatric co-morbidity (odds ratio \[OR\] 3.374, 95% confidence interval \[CI\] 1.177--9.673, *p* = 0.024) and psychotropic side effects (OR 5.782, 95% CI: 1.636--20.430, *p* = 0.006) (Table [4](#Tab4){ref-type="table"}), after adjusting for all factors that were significant as well as birth order and diagnosis, which slightly fell short of being significant, with *p* values of 0.063 and 0.068 respectively, on Chi-square test.Table 3Association between clinical variables and polypharmacy in children and adolescents with psychiatric disorders in Botswana, January 2012 to July 2016Risk factorsMono --pharmacy\
N (%)Polypharmacy N (%)*df*χ^2^*p*Age group ≤1027 (58.7)19 (41.3)15.319*0.021* \>1058 (78.4)16 (21.6)Gender Female29 (74.4)10 (25.6)10.3480.555 Male56 (69.1)25 (30.9)Birth order First born16(39.0)25(61.0)13.3220.068 Others17(23.0)57(77.0)Past psychiatric history Absent14 (58.3)10 (41.7)12.2690.132 Present71 (74.0)25 (26.0)Medical history Absent78 (71.6)31 (28.4)10.3070.582 Present7 (63.6)4 (36.4)Psychiatrist care Not given64 (66.0)33 (34.0)15.772*0.016* Given21 (91.3)2 (8.7)Psychiatric co-morbidity Absent43 (84.3)8 (15.7)17.802*0.005* Present42 (60.9)27 (39.1)Physical co-morbidity Absent77 (72.6)29 (27.4)11.4380.230 Present8 (57.1)6 (42.9)Diagnosis Externalizing disorders26 (60.5)17 (39.5)25.5240.063 Internalizing disorders7 (100)- Others52 (74.3)18 (25.7)Psychotropic side effect Absent75 (75.8)24 (24.2)16.640*0.010* Present10 (47.6)11 (52.4)Mode of care In-patient22 (71.0)9 (29.0)10.0000.985 Out-patient63 (70.8)26 (29.2)Type of intervention Only Pharmacological30 (68.2)14 (31.8)10.280.866 Both Psychological and pharmacological46 (69.7)20 (30.3)Significant *p*-value in italics, χ^2^ = Chi-square, *df* degree of freedom, *p* = *P* value Table 4Factors associated with polypharmacyRisk factorsWald*dfp*-valueOR95% CILowerUpperAge group^a^.8501.3561.786.5216.124Diagnosis^b^.0011.9741.021.2913.587Psychiatrist care^c^1.5571.212.347.0661.829Birth order^d^3.5031.061.376.1351.047Psychiatric comorbidity^e^5.1221*.024*3.3741.1779.673Psychotropic side effect^f^7.4241*.006*5.7821.63620.430Significant test of association in *italics, OR*  odds ratio, *CI*  confidence interval, *df*  degree of freedom^a^\> 10 years^b^Internalizing disorders^c^Psychiatrist care given^d^Others^e^Absent^f^Absent

Discussion {#Sec4}
==========

The prevalence of polypharmacy (29.2%) in this study is slightly outside the range of 2.9--27% reported in a systematic review by Toteja et al. \[[@CR11]\]. It is about two-fold the rate reported in a US study (13.8%) among paediatric patients at discharge from hospitalization, this is not surprising as our series covered in-patient and outpatient services \[[@CR11]\]. It is much less than the 52.4% reported in an Indian study and 51% by Dean et al. in Australia about a decade ago \[[@CR10], [@CR12]\]. However, our rate of 41.3% in the younger child compared to 21% in the older was in direct opposition to the trend; lower rates were reported in the younger child than adolescents \[[@CR11]\]. We cannot explain this difference given that the general adult psychiatrists employed at our centre treat mainly adults with mental health conditions and lack the expertise for complete treatment plan in children and adolescents, which prioritizes developmental and psychosocial interventions over psychotropic medications \[[@CR13], [@CR14]\]. Our results do indicate that polypharmacy is a common practice in our centre as in other parts of the world \[[@CR1], [@CR2], [@CR15]\].

The mean age of our sample 11.9 (4.4) years and a preponderance of male children (67.5%) was comparable to the mean of Toteja et al.'s systematic review of 15 studies that involved 58,041 subjects \[[@CR11]\]. We differed in the most commonly reported diagnoses: ours were those grouped under "others" such as epilepsy, enuresis, somatoform disorder, psychosis, conversion disorders, etc., while they reported more externalizing mental conditions hyperkinetic disorder and conduct disorder. Whereas mood disorders (internalizing conditions) accounted for the mostly treated mental illnesses with polypharmacy in the Indian study earlier mentioned \[[@CR10]\]. Our finding of 5.8% with internalizing disorders is too small a sample to derive meaningful conclusions. The pattern of presentation of psychiatric cases to our treatment centre restricts us to these groupings for convenience. These differences however highlight the complexity of child and adolescent mental disorders involved in polypharmacy all over the world.

An initial analysis did not find significant association with gender and diagnosis in keeping with previous studies \[[@CR10], [@CR11]\]. Our data showed that age group, psychiatrist care, psychiatric co-morbidity and psychotropic side effects influenced the rate of polypharmacy in our series. These variables including diagnosis were further analyzed with the logistic regression. Our results indicated that psychiatric co-morbidity and psychotropic side effects were significantly associated with the presence of polypharmacy as their odds ratio were high contrary to the findings of Russell et al. \[[@CR10]\]. However, other studies agreed with our findings that co-morbidity and more complex presentation (diagnosis that are not clear-cut) significantly correlate with the risk of polypharmacy \[[@CR12], [@CR15], [@CR16]\]. The pressure to quickly resolve patients' symptoms which make non-pharmacological options less attractive and favour an increase in polypharmacy with attendant psychotropic side effects have been reported by other investigators \[[@CR17], [@CR18]\].

Being a retrospective study, we could not explore if other risk factors were involved in polypharmacy in our centre. Another limitation of this study is the small number of subjects, which imposes restriction on the external validity of our results. We admit that while cases where switching of psychiatric medications were clear-cut from documentation were excluded; given the retrospective design, few cases could have been missed. There were some missing data: birth order as a variable was omitted for some patients which could have impacted our result. A prospective, long-term study would address these concerns. Despite these constraints, we believe this study has highlighted the practice of polypharmacy in paediatric psychiatric patients in Botswana and the need for specialized care of this population.

Conclusions {#Sec5}
===========

In conclusion, the prevalence of psychiatric polypharmacy was 29.2% among children and adolescents with psychiatric disorders in Botswana; co-morbidity and psychotropic side effects were significantly associated with the presence of polypharmacy.
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